Company intelligence
Eascra Biotech
Building the next generation of innovative therapeutic nanotechnologies
About Eascra Biotech
Based on DNA nanotechnology, our novel family of Janus base nanomaterials provides highly effective, super biocompatible solutions that enable enhanced therapeutic delivery and regenerative medicine for articular cartilage, central nervous system disorders, solid tumors, and other chronic conditions. Our three generations of DNA-inspired nanotubes are a cost-effective alternative to existing options, and they have excellent scalability. We can customize our Janus base nanotechnologies to enhance the therapeutic efficacy of drug treatments for a variety of chronic conditions and medical needs.
Verified activity
Signals from Eascra Biotech
3 published signals
Presence & Recognition
Eascra Biotech is supported by Massachusetts Biomedical Initiatives colleagues and friends throughout the startup journey.
Reported by Eascra Biotech
People
Eascra Biotech welcomed Dr. Andrew Goodearl to the team.
Reported by Mari Anne Snow
Presence & Recognition
Eascra Biotech was awarded a 796 million dollar NASA activity.
Reported by Mari Anne Snow